Castuner

Medsolve Dynamics

Medsolve Dynamics

Short, operator-level strategy for radiation oncology and cancer program leaders navigating margin pressure, capital decisions, and AI reality. No fluff. No pitch. Just what the vendor isn't telling you.

Listen in your app

Episodes

82 episodes

  1. Know the number before the denial. 1:28
  2. Two different things 1:10
  3. Two clocks: the rule moves, your budget doesn't. 1:03
  4. The machine passes. The plan is not tested. 1:49
  5. Benchmark what you own 1:46
  6. It Would Have Been My Machine: The Oncology Operator, Issue 007 0:59
  7. LINAC Service Contract Rate vs Service Cost: One Number to Check Before You Sign 1:09
  8. The Alternative Does Not Have to Win (AMAC Summer Seminar 2026) 2:02
  9. The Number With No Counterparty 1:27
  10. The Escalator Nobody Argues About 1:05
  11. Sixteen Months of Ordinary Course 1:16
  12. The Half-Million-Dollar Anchor 1:59
  13. Price the AI, Not the Demo: Two Questions Before You Buy Theranostics Response-Monitoring Software 1:27
  14. Running the Theranostics Plan at Drug Margin Zero 1:44
  15. Why a One-Hour LINAC downtime Becomes a Three-Hour Day in Radiation Oncology 2:12
  16. The Tell in a LINAC Service Contract: Same Rate on a New Machine and a Twenty-Year-Old One 2:19
  17. What Every New Radiation Oncology Administrator Should Know Before Their First Vendor Meeting 1:50
  18. Why a Discount Off List Is Not a Number You Can Trust in Radiation Oncology Capital 1:28
  19. Why AI Efficiency Disappears Between the Demo and the Staffing Model. 1:09
  20. Why a Radioligand No-Show Costs Differently Than a Missed Fraction. 1:29
  21. Why AI Is Not a One-Time Purchase in Radiation Oncology 1:36
  22. Why a Theranostics No-Show Hurts Differently Than an IMRT One 1:35
  23. A Guideline Says It Is Appropriate. The Next Question Is Whether Your Program Can Deliver It. 1:45
  24. The Service Contract Renewal Conversation Most Rad Onc Programs Have Already Lost 1:28
  25. The Vendor Landscape Just Widened. Your Capital Conversation Changed Whether You Know It Or Not. 1:23
  26. The Hospital Math Says Build. The Physician Math Says Do Not. That Gap Is The wRVU Trap. 2:33
  27. Ask The Vendor What The Same Software Costs Without The AI. The Unbundled-Price Question 1:29
  28. When I Was On The Vendor Side: The AI Demo That Skipped The Workflow Question 1:15
  29. Why Your LINAC's Unbooked Hours Are The Cheapest Margin Audit You Will Run In 2026 1:14
  30. What Does This Commit Us To In Year Five? The Question Every Oncology Capital Decision Needs 0:51
  31. The Proforma Altitude Problem In 2026 Oncology Capital Decisions 0:43
  32. Adding Benign Disease Is A Referral Decision, Not An Equipment Decision 1:19
  33. Theranostics Capital Decisions Are Build-Or-Partner Decisions, Not Product Decisions 1:41
  34. Capital Is A 7-10 Year Commitment: The Math Most Proformas Skip 1:28
  35. After 20 Years Selling LINACs, This Is What I Saw From The Vendor Side 1:16
  36. Why The Old Capital Math Does Not Survive The 2026 Reimbursement Environment 0:26
  37. Why Vendor Proformas Don’t Survive Year Two: A Capital Decision Reality Check 1:18
  38. Where Volume Responsibility Belongs in an Oncology Program | Jeff Siupik 0:51
  39. Running a Cancer Program in 2026: Capital, Operations, and the Job Behind the P&L 21:46
  40. Staff Is The Soul Of Your Program: Capital Discipline For Oncology Hiring And AI Tools 0:55
  41. The Service Contract Autopilot Problem: A 14-Year Veteran Explains 0:28
  42. I Loved Selling Bundles: 20 Years On The Vendor Side Of LINAC Capital 0:56
  43. Negotiating Inside a Structure the Vendor Built Before You Arrived 0:31
  44. After 20 Years on the Vendor Side, What Medsolve Does for Cancer Programs 1:20
  45. Why Most Oncology Service Contracts Quietly Cost Programs Money 0:45
  46. AI Procurement Accountability in Healthcare: 3 Questions Before You Sign 1:40
  47. Can you afford it at 80% of the current reimbursement? 0:35
  48. The allure of new technology without a clear problem to solve! 0:46
  49. Preparation and Anticipation in Vendor Negotiations 0:46
  50. Key provisions that can have a significant financial impact. 1:09